173 related articles for article (PubMed ID: 15897671)
21. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs.
Zembowicz A; Mastalerz L; Setkowicz M; Radziszewski W; Szczeklik A
Arch Dermatol; 2003 Dec; 139(12):1577-82. PubMed ID: 14676074
[TBL] [Abstract][Full Text] [Related]
22. Oral drug challenges in non-steroidal anti-inflammatory drug-induced urticaria, angioedema and anaphylaxis.
Chaudhry T; Hissaria P; Wiese M; Heddle R; Kette F; Smith WB
Intern Med J; 2012 Jun; 42(6):665-71. PubMed ID: 21981353
[TBL] [Abstract][Full Text] [Related]
23. Challenge-based clinical patterns of 223 Spanish patients with nonsteroidal anti-inflammatory-drug-induced-reactions.
Quiralte J; Blanco C; Delgado J; Ortega N; Alcntára M; Castillo R; Anguita JL; Sáenz de San Pedro B; Carrillo T
J Investig Allergol Clin Immunol; 2007; 17(3):182-8. PubMed ID: 17583106
[TBL] [Abstract][Full Text] [Related]
24. The safety of celecoxib in patients with aspirin-sensitive asthma.
Woessner KM; Simon RA; Stevenson DD
Arthritis Rheum; 2002 Aug; 46(8):2201-6. PubMed ID: 12209526
[TBL] [Abstract][Full Text] [Related]
25. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity.
Sánchez-Borges M; Capriles-Hulett A
Ann Allergy Asthma Immunol; 2000 Jan; 84(1):101-6. PubMed ID: 10674573
[TBL] [Abstract][Full Text] [Related]
26. Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs.
Quiralte J; Delgado J; Sáenz de San Pedro B; López-Pascual E; Nieto MA; Ortega N; Florido JF; Conde J
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):360-4. PubMed ID: 15521372
[TBL] [Abstract][Full Text] [Related]
27. Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases.
Fraj J; Valero A; Vives R; Pérez I; Borja J; Izquierdo I; Picado C
Allergy; 2008 Jan; 63(1):112-5. PubMed ID: 18053020
[TBL] [Abstract][Full Text] [Related]
28. Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients.
Bavbek S; Celik G; Pasaoglu G; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(1):57-62. PubMed ID: 16599250
[TBL] [Abstract][Full Text] [Related]
29. Are drug provocation tests still necessary to test the safety of COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity?
Çelik GE; Erkekol FÖ; Aydın Ö; Demirel YS; Mısırlıgil Z
Allergol Immunopathol (Madr); 2013; 41(3):181-8. PubMed ID: 23031659
[TBL] [Abstract][Full Text] [Related]
30. [Celecoxib in NSAID-induced cutaneous and respiratory adverse reactions].
Valero A; Enrique E; Baltasar M; Cisteró A; Martí E; Picado C
Med Clin (Barc); 2003 Nov; 121(18):695-6. PubMed ID: 14651817
[TBL] [Abstract][Full Text] [Related]
31. Provocation tests with the offending nonsteroidal anti-inflammatory drugs in patients with urticaria/angioedema reactions.
Zisa G; Riccobono F; Bommarito L; D'Antonio C; Calamari AM; Poppa M; Moschella MA; Di Pietrantonj C; Galimberti M
Allergy Asthma Proc; 2012; 33(5):421-6. PubMed ID: 23026184
[TBL] [Abstract][Full Text] [Related]
32. [Urticaria--angioedema induced by non-steroidal anti-inflammatory analgesics].
Díez Gómez ML; Alvarez Cuesta E; Hinojosa Macías M; García Cañadillas F; Alcover Sánchez R
Allergol Immunopathol (Madr); 1984; 12(3):179-88. PubMed ID: 6332509
[TBL] [Abstract][Full Text] [Related]
33. NSAID hypersensitivity (respiratory, cutaneous, and generalized anaphylactic symptoms).
Sánchez-Borges M
Med Clin North Am; 2010 Jul; 94(4):853-64, xiii. PubMed ID: 20609867
[TBL] [Abstract][Full Text] [Related]
34. Anaphylaxis to celecoxib.
Levy MB; Fink JN
Ann Allergy Asthma Immunol; 2001 Jul; 87(1):72-3. PubMed ID: 11476468
[TBL] [Abstract][Full Text] [Related]
35. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
Goldstein JL; Silverstein FE; Agrawal NM; Hubbard RC; Kaiser J; Maurath CJ; Verburg KM; Geis GS
Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
[TBL] [Abstract][Full Text] [Related]
36. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) - classification, diagnosis and management: review of the EAACI/ENDA(#) and GA2LEN/HANNA*.
Kowalski ML; Makowska JS; Blanca M; Bavbek S; Bochenek G; Bousquet J; Bousquet P; Celik G; Demoly P; Gomes ER; Niżankowska-Mogilnicka E; Romano A; Sanchez-Borges M; Sanz M; Torres MJ; De Weck A; Szczeklik A; Brockow K
Allergy; 2011 Jul; 66(7):818-29. PubMed ID: 21631520
[TBL] [Abstract][Full Text] [Related]
37. Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocation.
Kleinhans M; Linzbach L; Zedlitz S; Kaufmann R; Boehncke WH
Contact Dermatitis; 2002 Aug; 47(2):100-2. PubMed ID: 12423408
[TBL] [Abstract][Full Text] [Related]
38. Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs.
Nettis E; Colanardi MC; Ferrannini A; Vacca A; Tursi A
Ann Allergy Asthma Immunol; 2005 Nov; 95(5):438-42. PubMed ID: 16312166
[TBL] [Abstract][Full Text] [Related]
39. Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance.
Celik G; Paşaoğlu G; Bavbek S; Abadoğlu O; Dursun B; Mungan D; Misirligil Z
J Asthma; 2005 Mar; 42(2):127-31. PubMed ID: 15871445
[TBL] [Abstract][Full Text] [Related]
40. Evaluating the negative predictive value of provocation tests with nonsteroidal anti-inflammatory drugs.
Defrance C; Bousquet PJ; Demoly P
Allergy; 2011 Nov; 66(11):1410-4. PubMed ID: 21722141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
